IL6 and rheumatoid arthritis: Rheumatoid arthritis and almost all other autoimmune diseases are associated with the risk of cardiovascular disease through systemic inflammation by direct and indirect effects [7], and the relation between disease activity and treatments, mainly IL-6 tocilizumab and cardiovascular risk, has never been studied in the Middle East and especially in the Kingdom of Saudi Arabia.